Abstract
Amnesia can be induced in rats in the passive avoidance paradigm by administration of scopolamine, a central muscarinic receptor antagonist. Tacrine or galanthamine, inhibitors of acetylcholinesterase, given in conjunction with scopolamine partially reversed the scopolamine-induced deficit in passive avoidance performance. Four so-called cognitive enhancers, all widely used for the treatment of the symptoms associated with mental aging, cerebral insufficiency and senile memory disorder, were investigated in this paradigm. Piracetam, an extract of Ginkgo biloba, dihydroergocristine and a combination of raubasine with dihydroergocristine, all attenuated the amnesia induced by scopolamine. In contrast, nicergoline had no significant effect. Raubasine alone also failed to significantly attenuate scopolamine-induced amnesia, although some doses of raubasine had a non-significant tendency (P<0.10) to reduce the amnesia.
Similar content being viewed by others
References
Arrigo A, Moglia A, Borsotti L (1982) A double-blind, placebo-controlled, cross-over trial with nicergoline in patients with senile dementia. Int J Clin Pharmacol Res 2:33–41
Bailly A, Roux C, Bourgeois M (1974) Etude d'Iskédyl dans les troubles cerebro-vasculaires de sujet âgé. Synthése 2:57–59
Baraka A, Harik S (1977) Reversal of central anticholinergic syndrome by galanthamine. JAMA 238:2293–2294
Bartus RT, Johnson HR (1976) Short-term memory in the rhesus monkey: disruption from the anti-cholinergic scopolamine. Pharmacol Biochem Behav 5:39–46
Bartus RT, Dean RL, Beer B, Lippa AS (1982) The cholinergic hypothesis of geriatric memory dysfunction: a critical review. Science 217:408–417
Briley M (1985) Neuropharmacological profile of the association raubasine-dihydroergocristine. Circ Metab Cerveau 2 [suppl 1]:161–175
Briley M, Moret C (1985) Inhibitory effect of dihydroergocristine on 5HT release from rat hypothalamic slices. Br J Pharmacol 83:353P
Chopin P, Briley M (1990) The effects of raubasine and dihydroergocristine on an age-related deficit in passive avoidance learning in rats. J Pharm Pharmacol 42:375–376
Chouinard G, Annable L, Ross-Chouinard A, Olivier M, Fontaine F (1983) Piracetam in elderly psychiatric patients with mild diffuse cerebral impairment. Psychopharmacology 81:100–106
De Souza RJ, Robinson TN, Cross AJ, Green AR (1989) The effects of tetrahydroaminoacridine on endogenous 5-hydroxytryptamine and dopamine release from rat brain slices. Br J Pharmacol 93:352P
Drachman DA, Leavitt J (1974) Human memory and the cholinergic system: a relationship to aging? Arch Neurol 30:113–121
Drukarch B, Leysen JE, Stoof JC (1988) Further analysis of the neuropharmacological profile of 9-amino-1,2,3,4-tetrahydroaminoacridine (THA), an alleged drug for the treatment of Alzheimer's disease. Life Sci 42:1011–1017
Dunnett SB (1985) Comparative effects of cholinergic drugs and lesions of nucleus basalis or fimbra-fornix on delayed matching in rats. Psychopharmacology 87:357–363
D'Urso R, Falaschi P, Jallamo R, Ruggieri S (1982) Effect of dihydroergocristine on prolactin release from isolated and dispersed rat pituitary cells. Acta Therap 8:109–114
Flood JF, Cherkin A (1986) Scopolamine effects on memory retention in mice: a model of dementia? Behav Neurol Biol 45:169–184
Giurgea CE, Salama M (1977) Nootropic drugs. Prog Neuropsychopharmacol 1:235–247
Glick SD, Zimmerberg B (1972) Amnesic effects of scopolamine. Behav Biol 7:245–254
Grau M, Montero JL, Balasch J (1987) Effect of piracetam on electrocortigram and local cerebral glucose utilization in the rat. Gen Pharmacol 18:205–211
Growdon JH, Corkin S, Huff FJ, Rosen TJ (1986) Piracetam combined with lecithin in the treatment of Alzheimer's disease. Neurobiol Aging 7:269–276
Hindmarch I (1986) Activité de l'extrait de Ginkgo biloba sur la mémoire a court terme. Presse Méd 15:1592–1594
Hugonot R, Israël L, Hugonot L (1985) Clinical trial of the effects of a combination of raubasine and dihydroergocristine on psycho-behavioural manifestations in elderly subjects: methodology and results. Circ Metab Cerveau 2 [suppl 1]:176–188
Hunter AJ, Murray TK, Jones JA, Cross AJ, Green AR (1989) The cholinergic pharmacology of tetrahydroaminoacridine in vivo and in vitro. Br J Pharmacol 98:79–86
Izquierdo I (1991) Role of NMDA receptors in memory. TIPS 12:128–129
Ketchum JS, Sidell FR, Crowell EB, Aghajanian GK, Hayes AH (1973) Atropine, scopolamine and ditran: comparative pharmacology and antagonists in man. Psychopharmacologia 28:121–145
Kito G (1990) Effects of vinpocetine and nicergoline on cerebral blood flow in anaesthetized dogs. Jpn J Pharmacol Ther 18:119–130
Lenègre A, Chermat R, Avril I, Stéru L, Porsolt D (1987) Specificity of piracetam's anti-amnesic activity in three models of amnesia in the mouse. Pharmacol Biochem Behav 29:625–629
Levy R (1987) Tetrahydroaminoacridine and Alzheimer's disease. Lancet i:332
Markstein R (1983) Dopamine receptor profile of co-dergocrine (Hydergine) and its components. Eur J Pharmacol 86:145–155
Nicholson CD (1990) Pharmacology of nootropics and metabolically active compounds in relation to their use in dementia. Psychopharmacology 101:147–159
Okuyama S, Aihara H (1988) Action of nootropic drugs on transcallosal responses in rats. Neuropharmacology 27:67–72
Osterreieder W (1987) 9-Amino-1,2,3,4-tetrahydroaminoacridine (THA) is a potent blocker of cardiac potassium channels. Br J Pharmacol 92:521–525
Pedata F, Moroni F, Pepeu GC (1984) Effect of nootropic agents on brain cholinergic mechanisms. Clin Neuropharmacol 7:772–773
Perry EK, Tomlinson BE, Blessed G, Bergmann K, Gibson PH, Perry RH (1978) Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. BMJ 11:1457–1459
Piercey MF, Vogelsang GD, Franklin SR, Tang AH (1987) Reversal of scopolamine-induced amnesia and alterations in energy metabolism by the nootropic piracetam: implications regarding identification of brain structures involved in consolidation of memory traces. Brain Res 424:1–9
Rapin JR, Le Poncin Lafitte M (1979) Modèle expérimental d'ischémie cérébrale. Action préventive de l'extrait de Ginkgo. Semaine des Hôpitaux de Paris 55:42–43
Roquebert J, Gomond P, Demichel P (1981) Activité antinoradrénergique de la raubasine sur l'aorte thoracique et le canal déférent isolé de rat. J Pharmacol (Paris) 12:393–400
Roquebert J, Demichel P, Gomond P, Malek A (1983) Activité de la dihydroergocristine sur les alpha-adrénorécepteurs pré et postsynaptiques du canal déférent isolé de rat. J Pharmacol (Paris) 14:151–159
Satoh M, Ishihara K, Iwana T, Tagaky H (1986) Aniracetam augments, and midazolam inhibits the long-term potentiation in guinea-pig hippocampal slices. Neurosci Lett 68:216–220
Shintomi K, Egou H, Tanaka T, Itakura T, Yoshimoto K, Matsumoto M, Matsuoka Y (1986) Pharmacological study of nicergoline (I): Protective effect against anoxic brain damages in animals. Folia Pharmacol Jpn 87:445–456
Stegink AJ (1972) The clinical use of piracetam, a new nootropic drug. Arzneimittelforschung 22:975–979
Stevens DR, Cotman CW (1987) Excitatory actions of tetrahydroaminoacridine (THA) on hippocampal pyramidal neurons. Neurosci Lett 79:301–305
Summers WK, Majovski LV, March GM, Tachiki K, Kling A (1986) Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. N Engl J Med 315:1241–1245
Tariot PN, Caine ED (1987) Oral tetrahydroaminoacridine in the treatment of senile dementia, Alzheimer's type. N Engl J Med 316:1604–1605
Taylor JE (1986) Liaisons des neuromédiateurs à leurs récepteurs dans le cerveau de rats: effet de l'administration chronique de l'extrait de Ginkgo biloba. Presse Méd 15:1491–1493
Tea S, Clesis P, Clanet M, Marc-Vergnes JP (1979) Effets cliniques hémodynamiques et métaboliques de l'extrait de Ginkgo biloba en pathologie vasculaire cérébrale. Gaz Méd France 86:4149–4152
Thouvenot P, Guerci O, Laurens MH (1984) Alterations in cerebral blood flow and behavioural changes in elderly patients treated with nicergoline. Psychol Med (Paris) 16:1571–1585
Vorberg G (1985) Ginkgo biloba extract (GBE): a long-term study of chronic cerebral insufficiency in geriatric patients. Clinical Trials J 22:149–157
Wesnes K, Anand R, Simpson P, Christmas L (1990) The use of a scopolamine model to study the potential nootropic effects of aniracetam and piracetam in healthy volunteers. J Psychopharmacol 4:219–232
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Chopin, P., Briley, M. Effects of four non-cholinergic cognitive enhancers in comparison with tacrine and galanthamine on scopolamine-induced amnesia in rats. Psychopharmacology 106, 26–30 (1992). https://doi.org/10.1007/BF02253584
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02253584